Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Feb 13, 2019

PTC Therapeutics Launches Fifth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy

- STRIVE Awards have Supported Over 20 Projects in 15 Countries- -Grant Proposals from Nonprofit Patient Advocacy Organizations Due April 30- SOUTH PLAINFIELD, N.J. , Feb. 13, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the fifth annual STRIVE grant

Jan 31, 2019

PTC Therapeutics Launches New Program to Support Research Projects in Rare, Genetic Disorders

- $500,000 funding to improve Duchenne muscular dystrophy diagnosis and screening in 2019 - SOUTH PLAINFIELD, N.J. , Jan. 31, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today launched PRIORITY, an annual funding program for innovative research.

Jan 25, 2019

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , Jan. 25, 2019 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on January 22, 2019 it approved non-statutory stock options to purchase an aggregate of 170,050 shares of its common stock to 24 new employees.

Jan 23, 2019

PTC Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH PLAINFIELD, N.J. , Jan. 23, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today the pricing of a public offering of 6,720,000 shares of its common stock at a public offering price of $30.20 per share, before underwriting discounts.

Jan 22, 2019

PTC Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH PLAINFIELD, N.J. , Jan. 22, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) announced today that it is commencing a public offering of $200 million of shares of its common stock. All of the shares in the offering are to be sold by PTC.

Jan 07, 2019

PTC Therapeutics Announces Executive Team Updates Focused on Accelerating Pipeline and Bringing Gene Therapy Manufacturing In-house

SOUTH PLAINFIELD, N.J. , Jan. 7, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Dr. Mark Pykett to Chief Scientific Officer and Dr. Neil Almstead to Chief Technical Operations Officer. "Achievement of our long-term strategy requires accelerating our

Jan 07, 2019

PTC Therapeutics Provides Corporate Update and Outlines 5-year Strategic Plan at 2019 J.P. Morgan Healthcare Conference

- Multiple products to be launched by 2023 potentially generating ~$1.5 billion revenue annually- - Plan to submit BLA in 2H 2019 for AADC gene therapy program - - Risdiplam regulatory filing targeted for 2H 2019 - - TEGSEDI™ filed in Brazil for expected approval in 2019 - - Duchenne franchise

Jan 02, 2019

PTC Therapeutics to Participate at Upcoming Investor Conference

SOUTH PLAINFIELD, N.J. , Jan. 2, 2019 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company update at the J.P. Morgan Healthcare Conference on Tuesday, January 8 th at 5 p.m. PST . The presentation will be webcast live on the Events and

Dec 20, 2018

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , Dec. 20, 2018 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on December 17, 2018 it approved non-statutory stock options to purchase an aggregate of 24,500 shares of its common stock to 5 new employees.

Dec 18, 2018

PTC Therapeutics Deepens Financial and Commercial Expertise of Board with Two New Appointments

SOUTH PLAINFIELD, N.J. , Dec. 18, 2018 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Emma Reeve and Stephanie Okey to the Company's Board of Directors. Ms. Reeve currently serves as the Chief Financial Officer of Constellation Pharmaceuticals, Inc.

Pagination

First page
Previous page
…
Page 27
Page 28
Current page 29
Page 30
Page 31
…
Next page
Last page